Search

everythinglearnresearchcommunity

for

Search:↓

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.

Psoriasis treatment may affect body hair growth, with a complex relationship between skin and hair growth mechanisms.

Blocking certain proteins can significantly regrow hair in severe alopecia areata.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.

Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Etanercept effectively treated a severe skin condition when other treatments failed.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Etanercept improved symptoms of a specific type of psoriatic arthritis in a patient who didn't respond to other treatments.

A medication may help with hair growth in psoriasis, and a skin condition might be linked to a specific bacteria.

Ixekizumab has known and some unexpected side effects.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Some systemic treatments work for nail psoriasis but can have serious side effects.

Dupilumab for eczema may cause hair loss.

Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.

Dermoscopy helps diagnose unusual skin lesions like osteonevus of Nanta and can prevent misdiagnosis of serious conditions.

New therapies for rare skin diseases show promise but need more research.

Acitretin may cause salivary gland inflammation.

Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.